Itraconazole interferes in the pharmacokinetics of fuzuloparib in healthy volunteers-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Itraconazole interferes in the pharmacokinetics of fuzuloparib in healthy volunteers

Published:2023-05-11 Issue:6 Volume:91 Page:523-529
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Hu Chaoying^ORCID,Zhang Yanping,Pei Tong,Liu Ping,Zhang Lan

Funder

Capital Science and Technology Leading Talent Training Project

Beijing Hospitals Authority Ascent Plan

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-023-04536-5.pdf

Reference22 articles.

1. Wang L, Yang C, Xie C et al (2019) Pharmacologic characterization of fuzuloparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials. Cancer Sci 110(3):1064–1075. https://doi.org/10.1111/cas.13947

2. Morales J, Li L, Fattah FJ et al (2014) Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit Rev Eukaryot Gene Expr 24:15–28

3. Michelena J, Lezaja A, Teloni F et al (2018) Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance. Nat Commun 9:2678

4. Lee A (2021) Fuzuloparib: first approval. Drugs 81(10):1221–1226. https://doi.org/10.1007/s40265-021-01541-x

5. Luo J, Dai X, Hu H et al (2020) Fuzuloparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials. J Cancer Res Clin Oncol 146(3):721–737. https://doi.org/10.1007/s00432-019-03097-6

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of UPLC–MS/MS method for studying the pharmacokinetic interactions of fuzuloparib with curcumin in rats;Journal of Pharmaceutical and Biomedical Analysis;2024-10

2. Effect of food on the pharmacokinetics and safety profiles of a new PARP inhibitor fuzuloparib capsules in healthy volunteers;Cancer Chemotherapy and Pharmacology;2024-05-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3